Traws Pharma, Inc. announced on June 3, 2025, the publication of key clinical efficacy data for rigosertib, a legacy oncology asset, in patients with RDEB-associated squamous cell carcinoma (RDEB SCC). The findings were detailed in the British Journal of Dermatology.
The published results indicated a compelling overall response rate of 80%, with complete responses observed in 50% of evaluable patients. This marks the first clinical trial of any experimental cancer therapeutic in this rare and complex monogenic disease, which has a substantial unmet medical need.
Interim CEO Iain Dukes stated that rigosertib is available for further development and commercialization, and the company is actively seeking an appropriate partner to advance this medicine towards approval. This positive data could enhance the attractiveness of rigosertib for potential collaborators.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.